查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1992428

人工心臟市场：按类型、应用、技术、最终用户和患者群体划分－2026-2032年全球市场预测

Artificial Heart Market by Type, Application, Technology, End User, Patient Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，人工心臟市场价值将达到 31.4 亿美元，到 2026 年将成长至 34.8 亿美元，到 2032 年将达到 68.1 亿美元，复合年增长率为 11.67%。

主要市场统计数据
基准年 2025 31.4亿美元
预计年份：2026年 34.8亿美元
预测年份 2032 68.1亿美元
复合年增长率 (%) 11.67%

此资源涵盖了人工心臟不断发展的现状，包括临床需求、创新趋势、监管复杂性和支付方考虑因素，为医疗保健相关人员。

人工心臟领域正处于紧迫的临床需求、技术创新和复杂的法律规范三者交汇的境地。近年来，设备耐用性、小型化和远端监测方面的进步，已使这项技术从实验性治疗方法转变为针对特定患者群体的实用、长期机械循环支持手段。同时，临床医生和医疗保健系统面临着不断变化的临床指南、日益重视的感染控制和抗凝血治疗，以及透过疗效和成本效益指标来证明其价值的日益增长的压力。

识别正在重塑人工心臟发展的变革性变化，包括小型化、耐用的机械循环支援平台、数位化整合以及增强临床效用的新型生物相容性材料。

多项变革正在重塑人工心臟生态系统，在创造新机会的同时，也重塑了竞争格局。首先，小型化和能源效率的技术进步使得人工心臟能够实现更小的外形规格和携带式使用，从而惠及更广泛的患者群体，并改变了植入手术的物流。同时，生物相容性涂层和血液相容性的改善降低了血栓形成和感染相关併发症的风险，也改变了人们对长期管理和追踪通讯协定的预期。

评估美国关税对人工心臟供应链、采购趋势、临床准入途径以及製造商和供应商对策略定价的应对措施的累积影响。

美国2025年实施的关税和贸易政策转变将对人工心臟供应链、筹资策略和临床应用模式产生多方面的影响。关税将增加许多先进医疗设备製造商赖以生存的进口零件和子组件的到货成本。对于那些从海外采购专用感测器、电机用稀土元素材料或精密加工零件的企业而言，这种影响尤其显着。因此，製造商被迫透过重新评估供应商组合、加快国内供应商的认证流程或调整内部利润率等措施来承担增加的成本。

为了明确设备类型、应用、技术、最终用户和患者人口统计的实际细分见解，并将这些见解反映在产品设计、临床引入和市场发布策略中。

精细化的市场区隔观点能够清楚展现临床需求、技术能力和商业性机会的契合点。基于类型，市场分析将产品分为“人工心臟”和“心室辅助装置”，其中心室辅助装置进一步细分为“双心室辅助装置”、“左心室辅助装置”和“右心室辅助装置”，以反映不同的临床适应症和植入复杂性。每种装置亚型都具有独特的技术权衡、后续要求和临床培训项目，这些因素共同决定了其在医疗机构中的部署模式。

确定美洲、欧洲、中东、非洲和亚太地区的关键区域因素，并协调监管流程、偿还模式和商业化计画。

区域趋势对监管时间表、报销方式和临床应用有显着影响。在美洲，集中且高品质的医疗中心、成熟的移植项目以及完善的医院采购流程，为高成本、高复杂度的医疗器材的推广创造了有利条件；与此同时，区域保险公司也越来越要求在核准报销前提供强有力的治疗效果证据。此外，在有影响力的学术机构的主导下，北美临床网络往往能够促进创新技术的采纳，而采购主导的联合采购则可以加速整个医疗系统的大规模应用。

本报告重点介绍了在人工心臟生态系统中塑造领导地位的企业层面的竞争与合作趋势、策略伙伴关係、智慧财产权趋势和投资模式。

人工心臟领域的企业活动呈现两种发展轨迹：一是成熟医疗设备製造商的持续投资，二是专业Start-Ups和大学衍生企业的敏捷创新。成熟公司通常专注于透过临床试验逐步改进，提高可靠性、减少不利事件并扩大适应症。同时，中小企业和大学附属团队则往往致力于突破性概念的研发，例如新型泵结构、替代能量传输机製或可最大限度减少宿主反应的生物材料，这些都可能成为战略伙伴关係和许可协议的理想目标。

为医疗设备製造商、临床领导者和支付方提供可操作的建议，以加快采用速度、优化价值提案并减少供应链和监管摩擦。

行业领导者可以采取多项切实可行的措施来加速技术应用并保持商业性发展势头。製造商应优先考虑模组化设计原则，以减少对关税敏感组件的依赖，并简化分阶段改进的监管申报流程。确保使用检验的替代供应商并对本地製造合作伙伴进行认证，可以降低供应链中断的风险，同时确保产品上市时间。此外，投资遥测和结果平台可以透过产生真实世界数据 (REW) 来提供竞争优势，而支付方和医疗保健系统对此类数据的需求日益增长。

我们将解释我们严谨的混合调查方法，该方法整合了临床证据评估、相关人员访谈、供应链分析和监管映射，以确保可靠的市场情报。

本研究采用混合调查方法，旨在透过交叉检验临床、商业性和监管观点，得出可靠且可操作的见解。此方法首先对同行评审的临床文献、监管申报文件和已发布的指南进行全面评估，以建立医疗设备安全性、有效性和适应症的证据基础。为了补充这一证据基础，研究人员还与包括心胸外科医生、心臟衰竭专家、医院采购经理、保险公司和医疗设备工程师在内的关键相关人员进行了结构化访谈，以收集实际见解和营运限制。

这项见解综合了技术、监管和商业性趋势，为人工心臟领域的策略决策和未来投资重点提供了指导。

技术成熟、临床通讯协定不断演进以及商业性趋势的转变，共同将人工心臟技术推向了转折点。设备工程和遥测技术的进步正在稳步降低传统上阻碍人工心臟广泛应用的障碍，但区域法规和医疗保险报销环境仍然影响着人工心臟的部署速度和模式。供应链压力和贸易政策的变化增加了复杂性，要求各机构透过多元化经营和短期营运规划来积极应对这些挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：人工心臟市场：依类型划分

  • 全人工心臟
  • 心室辅助装置
    • 双心室辅助装置
    • 左心室辅助装置
    • 右心室辅助装置

第九章：人工心臟市场：依应用领域划分

  • 移植前的过渡治疗
  • 最终治疗

第十章：人工心臟市场：依技术划分

  • 轴流式
  • 离心式
  • 电磁
  • 气动型

第十一章 人工心臟市场：依最终用户划分

  • 门诊手术中心
  • 医院
  • 专科诊所

第十二章：依患者群体分類的人工心臟市场

  • 成人
  • 儿童

第十三章 人工心臟市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 人工心臟市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 人工心臟市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国人工心臟市场

第十七章：中国人工心臟市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Abiomed, Inc.
  • Berlin Heart GmbH
  • BIOTRONIK SE & Co. KG
  • BiVACOR Inc.
  • Boston Scientific Corporation
  • Calon Cardio-Technology Ltd.
  • CARMAT SA
  • CorWave SA
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • Evaheart, Inc.
  • FineHeart SA
  • Getinge AB
  • Jarvik Heart, Inc.
  • Lepu Medical Technology Beijing Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • MicroPort Scientific Corporation
  • RealHeart AB
  • ReliantHeart, Inc.
  • Siemens Healthineers
  • Sun Medical Technology R&D Co., Ltd
  • SynCardia Systems, LLC
  • Terumo Corporation
Product Code: MRR-3204321AF691

The Artificial Heart Market was valued at USD 3.14 billion in 2025 and is projected to grow to USD 3.48 billion in 2026, with a CAGR of 11.67%, reaching USD 6.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.14 billion
Estimated Year [2026] USD 3.48 billion
Forecast Year [2032] USD 6.81 billion
CAGR (%) 11.67%

Framing the evolving artificial heart landscape through clinical demand, innovation trajectories, regulatory complexities and payer considerations to orient strategic decision-making across healthcare stakeholders

The artificial heart landscape sits at the intersection of acute clinical need, engineering innovation and complex regulatory oversight. Recent advances in device durability, miniaturization and remote monitoring have elevated the technology from experimental therapy toward viable long-term mechanical circulatory support for selected patient populations. At the same time, clinicians and health systems face evolving clinical guidelines, intensified focus on infection control and anticoagulation management, and mounting pressure to demonstrate value through outcomes and cost-effectiveness metrics.

This introduction synthesizes the key forces shaping device development and clinical adoption, framing how improvements in biocompatible materials, power management and digital telemetry are unlocking new care pathways. It establishes the context for strategic decision-making by manufacturers, hospital procurement teams and clinical leaders, emphasizing the need for integrated planning across R&D, regulatory strategy and health economics. By highlighting the prevailing clinical imperatives and the technological enablers that respond to them, this section sets the stage for deeper analysis of market dynamics, segmentation drivers and region-specific considerations that follow.

Identifying transformative shifts reshaping artificial heart development including miniaturization, durable mechanical circulatory support platforms, digital integration and novel biocompatible materials driving clinical utility

Several transformative shifts are redefining the artificial heart ecosystem, creating new opportunities while resetting competitive imperatives. First, engineering advances in miniaturization and power efficiency are enabling smaller form factors and ambulatory use, which in turn broaden candidate profiles and alter implantation logistics. Concurrently, improvements in biocompatible coatings and hemocompatibility have reduced thrombotic risk and infection-related complications, changing long-term management expectations and follow-up protocols.

Digital integration is another pivotal trend: the embedding of telemetry, remote monitoring and predictive analytics into device platforms supports proactive clinical interventions, reduces readmissions and enables data-driven value demonstrations to payers. On the regulatory front, accelerated approval pathways and more harmonized international standards are shortening time-to-clinic for incremental device updates, even as scrutiny around safety and post-market surveillance intensifies. Finally, the convergence of novel financing models, growing private capital interest and strategic partnerships between device specialists and broader medtech or technology firms is reshaping product roadmaps and commercialization strategies. Together, these shifts are transitioning artificial heart technologies from niche salvage therapies to increasingly mainstream options within complex heart-failure care pathways.

Assessing cumulative impact of United States tariffs on the artificial heart supply chain, procurement dynamics, clinical access pathways and strategic pricing responses by manufacturers and providers

The imposition of tariffs and trade policy shifts in the United States in 2025 has a multi-dimensional effect on the artificial heart supply chain, procurement strategies and clinical access models. Tariffs increase the landed cost of imported components and subassemblies that many advanced device manufacturers rely upon, particularly when specialized sensors, rare-earth materials for motors, or precision machining are sourced internationally. The immediate consequence is pressure on manufacturers to reassess supplier portfolios, accelerate qualification of domestic vendors, or absorb cost increases through internal margin adjustments.

Hospitals and ambulatory surgical centers respond to higher device acquisition costs by seeking stronger value propositions, longer device longevity assurances, bundled service contracts, and clearer evidence of reduced downstream utilization. Payers meanwhile intensify scrutiny of reimbursement pathways and may require more robust real-world outcomes data to justify higher payments. To preserve competitiveness, device developers pursue a combination of strategies including supplier diversification, localizing critical manufacturing steps, redesigning products to reduce cost-sensitive inputs, and negotiating longer-term supply agreements to hedge volatility.

Regulatory and procurement teams must also account for potential lead-time variability and customs-related delays; this amplifies the importance of inventory planning and contingency sourcing. In aggregate, tariffs act as a catalyst for deeper supply chain resilience planning and may accelerate strategic moves toward regional manufacturing hubs, without fundamentally altering the clinical rationale for mechanical circulatory support.

Delineating actionable segmentation insights across device type, application, technology, end users and patient demographics to inform product design, clinical adoption and go-to-market strategies

A granular segmentation lens clarifies where clinical need, technology capability and commercial opportunity align. Based on Type, market analysis differentiates between Total Artificial Heart and Ventricular Assist Device, with the Ventricular Assist Device category further subdivided into Biventricular Assist Device, Left Ventricular Assist Device, and Right Ventricular Assist Device to reflect differing clinical indications and implantation complexity. Each device subtype entails distinct engineering trade-offs, follow-up requirements and clinical training programs, which shape adoption patterns across care settings.

Based on Application, the distinction between Bridge To Transplant and Destination Therapy highlights divergent evidence expectations: Bridge To Transplant usage relies heavily on short-to-intermediate term reliability and compatibility with transplant pathways, whereas Destination Therapy demands long-term durability and quality-of-life metrics. Based on Technology, axial, centrifugal, electromagnetic and pneumatic platforms each present unique profiles in terms of hemocompatibility, power consumption and implant footprint, informing which patient populations and clinical scenarios they best serve. Based on End User, the variance among Ambulatory Surgical Centers, Hospitals and Specialty Clinics affects procedural throughput, perioperative staffing models and capital acquisition decisions. Finally, Based on Patient Group, differences between Adults and Pediatrics require tailored device sizing, physiological considerations and specialized clinical protocols. When integrated, these segmentation dimensions guide prioritized product development, targeted clinical trials and differentiated commercial strategies.

Uncovering critical regional considerations across the Americas, Europe Middle East and Africa, and Asia Pacific to align regulatory pathways, reimbursement models and commercialization plans

Regional dynamics materially influence regulatory timelines, reimbursement approaches and clinical uptake. In the Americas, concentrated centers of excellence, established transplant programs and mature hospital procurement processes create fertile ground for high-cost, high-complexity devices, while regional payers increasingly demand robust outcomes evidence to authorize reimbursement. North American clinical networks also tend to drive innovation adoption when led by influential academic centers, and procurement-led group purchasing can accelerate scale deployment across health systems.

In Europe, Middle East & Africa, regulatory fragmentation and heterogeneous reimbursement models shape a more phased adoption curve, with leading national health systems often piloting new technologies before broader roll-out. Reimbursement in several European markets hinges on health technology assessment outcomes and negotiation with national payers, which emphasizes the need for early engagement and real-world data generation. Regionally, countries in the Middle East and Africa present divergent infrastructure readiness and financing mechanisms, necessitating tailored market-entry strategies.

Across Asia-Pacific, rapid expansion of specialized cardiac centers, growing domestic medtech capabilities, and diverse payer landscapes create both competitive pressure and partnership opportunities. Several markets in the region favor local manufacturing partnerships and technology transfer agreements to support scale, while others prioritize fast regulatory pathways for devices addressing significant unmet clinical need. Recognizing these regional contrasts allows stakeholders to sequence market entry, evidence generation and commercial investments to maximize clinical impact and return on effort.

Highlighting competitive and collaborative company-level developments, strategic partnerships, IP trajectories, and investment patterns shaping leadership in the artificial heart ecosystem

Company-level activity in the artificial heart domain is characterized by a dual track of sustained investment from established medical device manufacturers and nimble innovation from specialized startups and academic spin-outs. Incumbent firms typically focus on incremental improvements to enhance reliability, reduce adverse events, and expand indications through clinical studies. Meanwhile, smaller companies and university-affiliated teams often pursue disruptive concepts-novel pump architectures, alternative energy transfer mechanisms, or biomaterials that minimize host response-which can become attractive targets for strategic partnerships or licensing deals.

Strategic collaborations are a recurring theme: clinical partnerships accelerate access to real-world data, contract manufacturing and supply chain alliances mitigate production risk, and co-development agreements with technology companies enhance telemetry and analytics capabilities. Intellectual property strategies, including targeted patenting and defensive portfolios, differentiate market positioning and influence M&A activity. Investment patterns show growing interest in platform technologies that enable modular upgrades, as well as services that bundle device provision with remote monitoring and outcomes management. Competitive advantage increasingly depends on integrated solutions that combine device performance with ecosystem services, regulatory acumen and scalable manufacturing.

Presenting actionable recommendations for device manufacturers, clinical leaders and payers to accelerate adoption, optimize value propositions and mitigate supply chain and regulatory friction

Industry leaders can take several pragmatic actions to accelerate adoption and safeguard commercial momentum. Manufacturers should prioritize modular design principles that reduce dependence on tariff-sensitive components and simplify regulatory submissions for incremental improvements. Establishing validated secondary suppliers and qualifying local manufacturing partners will reduce exposure to supply chain shocks while preserving time-to-market. Concurrently, investing in telemetry and outcomes platforms creates defensible differentiation by generating the real-world evidence payers and health systems increasingly require.

Clinical leaders should codify standardized implantation and follow-up pathways that capture consistent patient-reported and clinical outcomes, enabling comparative effectiveness assessments and supporting reimbursement discussions. Early engagement with payers to define value metrics, bundled payment options, and risk-sharing arrangements will facilitate smoother adoption. Payers and hospital systems should pilot payment models that align reimbursement with demonstrated reductions in readmissions, length of stay and downstream interventions, while ensuring patient access for high-need cohorts.

Across the ecosystem, stakeholders should collaborate on registries and cross-institutional data-sharing initiatives to accelerate evidence generation. A coordinated approach to regulatory strategy, supply chain resilience and value demonstration will materially increase the probability of sustained clinical adoption and commercial success.

Describing a rigorous mixed-methods research methodology blending clinical evidence appraisal, stakeholder interviews, supply chain analysis and regulatory mapping to ensure robust market intelligence

This research deploys a mixed-methods methodology designed to triangulate clinical, commercial and regulatory perspectives and produce robust, actionable intelligence. The approach begins with a comprehensive appraisal of peer-reviewed clinical literature, regulatory filings and published guidance to establish the evidence base for device safety, efficacy and indications. That foundation is complemented by structured interviews with a representative sample of stakeholders including cardiothoracic surgeons, heart failure specialists, hospital procurement leaders, payers and device engineers to capture experiential insight and operational constraints.

Supply chain analysis maps critical component flows, manufacturing dependencies and potential chokepoints, while regulatory mapping compares approval and post-market surveillance expectations across major jurisdictions. Where available, anonymized real-world data and registry summaries inform assessments of utilization patterns and outcomes. Findings are validated through cross-checks with industry experts and methodical reconciliation of qualitative and quantitative inputs. Throughout the process, emphasis is placed on transparency of assumptions, reproducibility of findings and clear articulation of limitations to ensure that end-users can confidently apply insights to strategic decisions.

Concluding insights that synthesize technological, regulatory and commercial trajectories to guide strategic decision-making and future investment priorities within the artificial heart domain

The convergence of technological maturation, evolving clinical protocols and shifting commercial dynamics positions artificial heart technologies at an inflection point. Advances in device engineering and telemetry are steadily reducing traditional barriers to broader adoption, while regional regulatory and reimbursement environments continue to shape the pace and pattern of uptake. Supply chain pressures and trade policy changes add complexity that organizations must proactively manage through diversification and near-term operational planning.

Strategically, the most successful stakeholders will be those that integrate product innovation with comprehensive evidence generation, resilient manufacturing strategies and payer-aligned value propositions. Collaboration across clinical, engineering and commercial teams will accelerate the translation of laboratory progress into clinical best practice. As devices become more embedded within longitudinal care models, the ability to demonstrate meaningful improvements in patient-centered outcomes and system-level efficiencies will determine which technologies achieve durable adoption and scale. This synthesis underscores the need for deliberate, data-driven action to realize the transformative potential of artificial heart solutions across care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Heart Market, by Type

  • 8.1. Total Artificial Heart
  • 8.2. Ventricular Assist Device
    • 8.2.1. Biventricular Assist Device
    • 8.2.2. Left Ventricular Assist Device
    • 8.2.3. Right Ventricular Assist Device

9. Artificial Heart Market, by Application

  • 9.1. Bridge To Transplant
  • 9.2. Destination Therapy

10. Artificial Heart Market, by Technology

  • 10.1. Axial
  • 10.2. Centrifugal
  • 10.3. Electromagnetic
  • 10.4. Pneumatic

11. Artificial Heart Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Artificial Heart Market, by Patient Group

  • 12.1. Adults
  • 12.2. Pediatrics

13. Artificial Heart Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Artificial Heart Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Artificial Heart Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Artificial Heart Market

17. China Artificial Heart Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Abiomed, Inc.
  • 18.7. Berlin Heart GmbH
  • 18.8. BIOTRONIK SE & Co. KG
  • 18.9. BiVACOR Inc.
  • 18.10. Boston Scientific Corporation
  • 18.11. Calon Cardio-Technology Ltd.
  • 18.12. CARMAT SA
  • 18.13. CorWave SA
  • 18.14. CryoLife, Inc.
  • 18.15. Edwards Lifesciences Corporation
  • 18.16. Evaheart, Inc.
  • 18.17. FineHeart SA
  • 18.18. Getinge AB
  • 18.19. Jarvik Heart, Inc.
  • 18.20. Lepu Medical Technology Beijing Co., Ltd.
  • 18.21. LivaNova PLC
  • 18.22. Medtronic plc
  • 18.23. MicroPort Scientific Corporation
  • 18.24. RealHeart AB
  • 18.25. ReliantHeart, Inc.
  • 18.26. Siemens Healthineers
  • 18.27. Sun Medical Technology R&D Co., Ltd
  • 18.28. SynCardia Systems, LLC
  • 18.29. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL HEART MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL HEART MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TOTAL ARTIFICIAL HEART, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BIVENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY LEFT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY RIGHT VENTRICULAR ASSIST DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AXIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AXIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AXIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY CENTRIFUGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY CENTRIFUGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY CENTRIFUGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ELECTROMAGNETIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ELECTROMAGNETIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ELECTROMAGNETIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PNEUMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PNEUMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PNEUMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. G7 ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. G7 ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NATO ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. NATO ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL HEART MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ARTIFICIAL HEART MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA ARTIFICIAL HEART MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA ARTIFICIAL HEART MARKET SIZE, BY VENTRICULAR ASSIST DEVICE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA ARTIFICIAL HEART MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA ARTIFICIAL HEART MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA ARTIFICIAL HEART MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA ARTIFICIAL HEART MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)